TWiV 823: COVID-19 clinical update #86 with Dr. Daniel Griffin

October 30, 2021

In COVID-19 clinical update #86, Dr. Griffin discusses virologic features of infection in children, antibody tests should not be used to asses level of protection, test-to-stay programs in schools, FDA authorizes Moderna boosters, results of TOGETHER trial for fluvoxamine, statins and 28 day mortality, and cognitive function in patients.

Hosts: Daniel Griffin and Vincent Racaniello

Click arrow to play
Download TWiV 823 (28 MB .mp3, 47 min)
Subscribe (free): iTunesGoogle PodcastsRSSemail

Become a patron of TWiV!

Links for this episode

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to

Leave a Reply

Your email address will not be published. Required fields are marked *

3 comments on “TWiV 823: COVID-19 clinical update #86 with Dr. Daniel Griffin

  1. Ian Light Oct 30, 2021

    When ought boosters be recommended ?
    In the future could a series of tests of immunity predict susceptibility to severe disease and death .
    Israeli study published in Lancet Friday 29 October showed markedly increased protection with triple vaccination .particularly for the aged .
    More cases are dropping markedly as are serious cases and deaths .

  2. Janelle Manou Nov 5, 2021

    Not sure if this has been addressed but a 36 year old woman experienced pericarditis following her Pfizer vaccine. Her doctors are reluctant to give her the second jab of either Pfizer or AZ. In Sydney Australia not being vaccinated has huge limitations for her and her three children. What are your thoughts??

  3. Jeu de Mots Nov 10, 2021

    I know you’ve covered various aspects of pcr vs rapid antigen tests on the podcast (I love the twiv podcast!!), but I still need a reminder: When our kids fly home from three different colleges in mid-December, which type of testing should we all use to hopefully avoid cooking up a big viral stew for the holidays? We have easy access to free pcr testing, or could buy rapid test kits.